|
WDR82 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.88459999944857E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.11009999999878E-05 |
| Normal-vs-Stage2 |
7.99089999999891E-05 |
| Normal-vs-Stage3 |
4.67859999964126E-07 |
| Normal-vs-Stage4 |
1.62690000027332E-07 |
| Stage1-vs-Stage2 |
2.755400E-01 |
| Stage1-vs-Stage3 |
8.678200E-02 |
| Stage1-vs-Stage4 |
3.135600E-02 |
| Stage2-vs-Stage3 |
8.836000E-01 |
| Stage2-vs-Stage4 |
6.202600E-01 |
| Stage3-vs-Stage4 |
6.453800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.50670000043496E-07 |
| Normal-vs-AfricanAmerican |
4.261700E-02 |
| Normal-vs-Asian |
1.235210E-03 |
| Caucasian-vs-AfricanAmerican |
2.407000E-01 |
| Caucasian-vs-Asian |
5.420600E-01 |
| AfricanAmerican-vs-Asian |
5.372200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.76420000012001E-08 |
| Normal-vs-Female |
3.5796999999782E-06 |
| Male-vs-Female |
2.312000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.54210000000199E-05 |
| Normal-vs-Age(41-60Yrs) |
1.87731999999885E-05 |
| Normal-vs-Age(61-80Yrs) |
7.88679999086384E-09 |
| Normal-vs-Age(81-100Yrs) |
7.440300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.490400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.766440E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.562000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.730500E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.990200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.757600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.934100E-02 |
| Classical-VS-Follicular |
1.583650E-04 |
| Classical-VS-Other |
2.030600E-01 |
| Classical-VS-Normal |
1.846360E-04 |
| Tall-VS-Follicular |
7.125200E-01 |
| Tall-VS-Other |
8.612800E-01 |
| Tall-VS-Normal |
1.73087999999488E-05 |
| Follicular-VS-Other |
9.835800E-01 |
| Follicular-VS-Normal |
7.65590000284533E-08 |
| Other-VS-Normal |
1.071850E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.10370000033977E-07 |
| Normal-vs-N1 |
4.73339999995659E-06 |
| N0-vs-N1 |
6.473600E-01 |
|
|
